Abstract

Hypofibrinogenaemia is associated with increased morbidity and mortality, but the optimal treatment level, the use of preemptive treatment and the preferred source of fibrinogen remain disputed. Fibrinogen concentrate is increasingly used and recommended for bleeding with acquired haemostatic deficiencies in several countries, but evidence is lacking regarding indications, dosing, efficacy and safety.
OriginalsprogEngelsk
TidsskriftCochrane Database of Systematic Reviews
Vol/bind8
Sider (fra-til)CD008864
ISSN1469-493X
DOI
StatusUdgivet - 2013

Fingeraftryk

Dyk ned i forskningsemnerne om 'Fibrinogen concentrate in bleeding patients'. Sammen danner de et unikt fingeraftryk.

Citationsformater